# CellaVision

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/cellavision).

## Overview

CellaVision is a global medical technology company specializing in the development and sale of advanced solutions for the routine analysis of blood and other body fluids. These solutions are crucial for accurate and swift disease diagnosis, particularly for infections and serious cancer diseases. The company's products, which include automated microscopy systems, replace manual laboratory work, enhancing workflow efficiency and skill development in healthcare facilities. Headquartered in Lund, Sweden, CellaVision operates through global partners and local support organizations in over 40 countries.

## Products & services

• Automated microscopy systems
• Reagents for hematology
• Digital Cell Morphology Software
• Sample preparation and image analysis tools
• Artificial intelligence for diagnostics
• Smearing and staining devices
• Bone Marrow Aspirate Application

- **Automated Microscopy Systems** (50%) — Includes systems for analyzing blood and body fluids.
- **Reagents** (20%) — Consumables used in hematology diagnostics.
- **Software & Other** (30%) — Digital tools and applications for laboratory workflows.

- Automated microscopy systems
- Reagents for hematology
- Digital Cell Morphology Software
- Sample preparation and image analysis tools
- Artificial intelligence for diagnostics
- Smearing and staining devices
- Bone Marrow Aspirate Application

## Customers

CellaVision primarily serves large laboratories and integrated health networks, which require efficient and accurate diagnostic solutions. The company's products are also used by smaller hospitals that are adopting automation to improve their diagnostic capabilities. Customers value CellaVision's technology for its ability to enhance workflow efficiency and diagnostic certainty. The company's global reach allows it to serve a diverse range of healthcare providers across different regions.

- **Large Laboratories** (primary) — Purchase automated systems for efficient diagnostics.
- **Integrated Health Networks** (primary) — Use solutions for accurate disease diagnosis.
- **Smaller Hospitals** (secondary) — Adopt automation to enhance diagnostic capabilities.

- Large laboratories seeking efficient diagnostic solutions
- Integrated health networks requiring accurate disease diagnosis
- Smaller hospitals adopting automation for improved diagnostics
- Healthcare providers valuing workflow efficiency and certainty
- Global reach serving diverse healthcare providers

## Geography

CellaVision operates globally, with significant market presence in the Americas, EMEA, and APAC regions. The company's headquarters are in Lund, Sweden, and it supports its global operations through 12 local market support organizations. The Americas represent a substantial portion of sales, driven by demand from large health networks. EMEA also contributes significantly, particularly in reagent sales, while APAC is a growing market for the company's innovative solutions.

- Global operations with headquarters in Lund, Sweden
- Significant market presence in Americas, EMEA, and APAC
- Americas driven by demand from large health networks
- EMEA significant in reagent sales
- APAC is a growing market for innovative solutions

## Strategy

CellaVision's strategic priorities focus on digitalizing microscopy workflows to enhance diagnostic certainty. The company aims to maximize its position in large laboratories and accelerate the adoption of its DC-1 system globally. Expanding leadership in reagents and exploring new analytics areas are also key priorities. These strategies are supported by a strong organizational culture and processes, aiming to establish a global standard for digital microscopy.

- **Maximize position in large laboratories** (medium-term) — To strengthen market leadership
- **Accelerate adoption of DC-1** (short-term) — To expand market reach
- **Expand leadership in reagents** (long-term) — To enhance product portfolio

- Digitalizing microscopy workflows for diagnostic certainty
- Maximize position in large laboratories
- Accelerate global adoption of DC-1 system
- Expand leadership in reagents
- Explore new areas of analytics

## Risks

CellaVision faces several risks, including reduced demand, currency fluctuations, and production disruptions. The company's reliance on global partners for sales exposes it to geopolitical risks, particularly in volatile regions. The medical technology industry also faces regulatory risks, as compliance with evolving standards is crucial. Additionally, technological advancements by competitors pose a risk to maintaining market leadership.

- **Currency fluctuations** [high] — Impact on profitability due to exchange rate changes
- **Production disruptions** [medium] — Potential supply chain issues affecting product availability

- Reduced demand impacting sales
- Currency fluctuations affecting profitability
- Production disruptions causing supply chain issues
- Geopolitical risks in volatile regions
- Regulatory risks with evolving standards
- Technological advancements by competitors

## Accounting

CellaVision applies IFRS standards, with revenue recognition being a critical area due to its global operations. The company faces currency effects due to its sales in multiple currencies, impacting reported earnings. The amortization of capitalized development expenses is another key area, affecting the company's gross margin. Consistent application of accounting policies is crucial for comparability across reporting periods.

- **Revenue recognition** — Significant on earnings
- **Currency effects** — Material on financial results

- Revenue recognition under IFRS standards
- Currency effects impacting reported earnings
- Amortization of capitalized development expenses
- Consistent application of accounting policies

---

*Last updated: 2026-08-11T04:04:51.537308+00:00*